The shares of SCHOTT Pharma AG & Co. KGaA, a global market leader for drug containment solutions and delivery systems, will be included in the SDAX for the first time as of 18 December 2023.
Andreas Reisse, CEO of SCHOTT Pharma, said: “Following our successful IPO just a little over 2 months ago, SCHOTT Pharma’s inclusion in the SDAX shows that investors have confidence in our business model and see the potential of our company."
"We look forward to building on this milestone, benefiting from increased visibility in the global capital markets, and pursuing our strategy.”
As part of the 160 most important shares listed on the Frankfurt stock exchange, the SDAX index comprises the 70 largest and most liquid companies following the DAX and MDAX in terms of market capitalisation.
The main criterion for the weighting of SDAX shares is market capitalization based on free float (minimum of 10%), which is around 23% for SCHOTT Pharma.
The company went public on September 28 this year on the Frankfurt Stock Exchange, marking the largest German IPO of 2023.
Dr Almuth Steinkühler, CFO of SCHOTT Pharma, said: “We saw a fantastic initial jump of the share price following our successful IPO, and we are delighted to now enter the SDAX as we remain well on track to meet our growth targets.”
